2026-04-29T07:24:19Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/186802024-09-27T12:03:15Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16981
Repisalud author Santoro, Francesco author Núñez-Gil, Ivan J author Vitale, Enrica author Viana-Llamas, María C author Romero, Rodolfo author Maroun Eid, Charbel author Feltes Guzman, Gisela author Becerra-Muñoz, Victor Manuel author Fernández Rozas, Inmaculada author Uribarri, Aitor author Alfonso-Rodriguez, Emilio author García Aguado, Marcos author Huang, Jia author Castro Mejía, Alex Fernando author Garcia Prieto, Juan Fortunato author Elola, Javier author Ugo, Fabrizio author Cerrato, Enrico author Signes-Costa, Jaime author Raposeiras Roubin, Sergio author Jativa Mendez, Jorge Luis author Espejo Paeres, Carolina author López Masjuan, Alvaro author Marin, Francisco author Guerra, Federico author El-Battrawy, Ibrahim author Cortese, Bernardo author Ramakrishna, Harish author Perez-Villacastín, Julian author Fernandez-Ortiz, Antonio author Brunetti, Natale Daniele 2024-02-27T15:08:42Z 2024-02-27T15:08:42Z 2022-06-22 http://hdl.handle.net/10668/20200 http://hdl.handle.net/20.500.12105/18680 35730631 10.1161/JAHA.121.024530 2047-9980 Journal of the American Heart Association Background COVID-19 is an infectious illness, featured by an increased risk of thromboembolism. However, no standard antithrombotic therapy is currently recommended for patients hospitalized with COVID-19. The aim of this study was to evaluate safety and efficacy of additional therapy with aspirin over prophylactic anticoagulation (PAC) in patients hospitalized with COVID-19 and its impact on survival. Methods and Results A total of 8168 patients hospitalized for COVID-19 were enrolled in a multicenter-international prospective registry (HOPE COVID-19). Clinical data and in-hospital complications, including mortality, were recorded. Study population included patients treated with PAC or with PAC and aspirin. A comparison of clinical outcomes between patients treated with PAC versus PAC and aspirin was performed using an adjusted analysis with propensity score matching. Of 7824 patients with complete data, 360 (4.6%) received PAC and aspirin and 2949 (37.6%) PAC. Propensity-score matching yielded 298 patients from each group. In the propensity score-matched population, cumulative incidence of in-hospital mortality was lower in patients treated with PAC and aspirin versus PAC (15% versus 21%, Log Rank P=0.01). At multivariable analysis in propensity matched population of patients with COVID-19, including age, sex, hypertension, diabetes, kidney failure, and invasive ventilation, aspirin treatment was associated with lower risk of in-hospital mortality (hazard ratio [HR], 0.62; [95% CI 0.42-0.92], P=0.018). Conclusions Combination PAC and aspirin was associated with lower mortality risk among patients hospitalized with COVID-19 in a propensity score matched population compared to PAC alone. eng COVID-19 Anticoagulation Antiplatelet therapy Aspirin Prognosis Risk prediction Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 Registry. research article